SCHEMBL6319919

SCHEMBL6319919

C=CCCCS(=O)(=O)NC(=O)c1ccc2[nH]c(C)c(Cc3ccc(Br)cc3Cl)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.38
MAPT P10636 9/20 0.36
PPARG P37231 1/20 0.36
TP53 P04637 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PTGS2 P35354 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
PTPN5 P54829 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MCL1 Q07820 3/20 0.34
ROCK2 O75116 1/20 0.33
ROCK1 Q13464 1/20 0.33
POLB P06746 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5882099 0.89 PPARG (0.46) CXCR2MAPTPPARGTP53SMN1; SMN2
SCHEMBL6320933 0.88 MAPT (0.40) MAPTPPARGTP53PTGS2MEN1
SCHEMBL6322250 0.84 CXCR2 (0.38) CXCR2MAPTPPARGTP53SMN1; SMN2
SCHEMBL6321322 0.82 PTGS2 (0.40) CXCR2MAPTPTGS2GAAPTPN5
SCHEMBL6135073 0.82 MAPT (0.41) CXCR2MAPTPPARGTP53SMN1; SMN2
SCHEMBL6135076 0.82 MAPT (0.41) CXCR2MAPTPPARGTP53SMN1; SMN2
SCHEMBL5881695 0.81 PPARG (0.51) MAPTPPARGPTGS2KDM4EL3MBTL1
SCHEMBL5882237 0.81 PPARG (0.47) MAPTPPARGPTGS2KDM4EPTPN5
SCHEMBL6319512 0.80 MGAM (0.43) CXCR2MAPTPTGS2GAA
SCHEMBL5881578 0.80 PPARG (0.55) MAPTPPARGL3MBTL1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US claimed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP claimed
EP-1599477-A1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-11-30 EP disclosed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
WO-2004074288-A1 SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-09-02 WO disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A CXCR2 2085/4885MAPT 3941/4885PPARG 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.